Netrin 1

NETRIS Pharma Doses First Patient in Phase 2 Study of NP137 for Checkpoint Inhibitor Resistance

Retrieved on: 
Tuesday, November 29, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, CFO, Immunoglobulin G, PD-1, Union, RECIST, Cell, Small and medium-sized enterprises, Cancer, SME, NCI-designated Cancer Center, OEIC, Patient, EIC, Transitional epithelium, Erosion (morphology), Organization, Instrument, Apoptosis, Uterine cancer, Ligand, Neoplasm, Netrin 1, Immunotherapy, Principal, Pharmaceutical industry, Medical imaging, Fine chemical, Melanoma

The enrollment of the first patient in ImmunoNET is a new clinical milestone for NETRIS Pharma.

Key Points: 
  • The enrollment of the first patient in ImmunoNET is a new clinical milestone for NETRIS Pharma.
  • Based on a unique mode of action of NP137 and biomarker studies conducted in Phase 1, we believe we can enlarge the fraction of responding patients and potentially prevent resistance, said Patrick Mehlen, CEO of NETRIS Pharma.
  • ImmunoNET has been specifically designed by clinicians to provide new solutions for patients suffering from resistance to immune-checkpoint inhibitors.
  • NETRIS Pharma, a clinical-stage company designs and develops anti-cancer therapeutic molecules, particularly monoclonal antibodies, to block the interaction between dependence receptors and their ligands.

NETRIS Pharma, Orano and Centre Léon Bérard Announce Scientific Collaboration to Develop Novel Antibody Radio-Conjugate Therapies

Retrieved on: 
Tuesday, September 20, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Drug resistance, NCI-designated Cancer Center, Director general, Center, Netrin 1, CLB, Safety, OEIC, Nuclear energy, Development, Epidemiology, Lã Đường, Immunoglobulin G, Neoplasm, Erosion (morphology), Innovation, Antibody, Partnership, EMT, Immunotherapy, Patient, Cancer, Ligand, Organization, Technology, Cell, Solution, Mab, Climate, Secretary of State for Universities, Research, Development and Innovation, Uterine cancer, Immune system, Edinburgh Cancer Research Centre, Radionuclide, Technology transfer, Vaccine, Pharmaceutical industry, Medical imaging, Orano

NETRIS Pharma SAS, a private clinical-stage biopharmaceutical company, announced today that it has entered into a scientific collaboration agreement with Orano and the Centre Lon Brard (CLB) to develop novel Antibody Radio-Conjugates for the treatment of cancer.

Key Points: 
  • NETRIS Pharma SAS, a private clinical-stage biopharmaceutical company, announced today that it has entered into a scientific collaboration agreement with Orano and the Centre Lon Brard (CLB) to develop novel Antibody Radio-Conjugates for the treatment of cancer.
  • Initially, the parties intend to conduct a preclinical proof-of-concept efficacy study with new radio-conjugate targeting Netrin-1, combining Netris monoclonal antibody (mAb) NP137 with undisclosed radioelement from Orano.
  • Both NETRIS Pharma and Orano have entered into this collaboration with Centre Lon Brard based on the potential opportunities brought by novel radioisotope conjugates in oncology.
  • NP137, a humanized monoclonal antibody of isotype IgG1 directed against netrin-1, is the first drug candidate developed by NETRIS Pharma.